<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8826866</article-id><article-id pub-id-type="pmc">2074723</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van Meerbeeck</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Debruyne</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>van Zandwijk</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Postmus</surname><given-names>P. E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pennucci</surname><given-names>M. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>van Breukelen</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Galdermans</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Groen</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pinson</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>van Glabbeke</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>van Marck</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Giaccone</surname><given-names>G.</given-names></name></contrib></contrib-group><aff>University of Antwerp, Belgium.</aff><pub-date pub-type="ppub"><month>9</month><year>1996</year></pub-date><volume>74</volume><issue>6</issue><fpage>961</fpage><lpage>963</lpage><abstract><p>The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with &#x0003c; 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00022-0129.tif" xlink:title="scanned-page" xlink:role="961" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00022-0130.tif" xlink:title="scanned-page" xlink:role="962" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00022-0131.tif" xlink:title="scanned-page" xlink:role="963" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

